title: [The use of recombinant human interleukin-1 alpha and -1 beta as agents in the early treatment of acute radiation sickness in an experiment].
abstract: Human recombinant interleukins 1 alpha and 1 beta (IL-1 alpha and IL-1 beta) have a good dose-dependent therapeutic effect for an acute radiation damage. For mice, the optimum therapy dose of IL-1 is 100.0 micrograms/kg-1 (survival rates: CD70--50%, CD100--17%; p < 0.05). For dogs, the dose is 1.0 microgram/kg-1 (survival rate: CD100 in combination with antibacterial therapy-up to 80%; p < 0.05).
authors.forename: S A
authors.initials: SA
authors.lastname: Rogacheva
authors.forename: A S
authors.initials: AS
authors.lastname: Simbirtsev
mesh_terms: D000208:Acute Disease; D000818:Animals; D016009:Chi-Square Distribution; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D011833:Radiation Injuries, Experimental / Q000188:drug therapy* / Q000401:mortality; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D007375:Interleukin-1; D011994:Recombinant Proteins
vernacular_title: Primenenie rekombinantnykh interleĭkinov-1 al'fa i -1 beta cheloveka v kachestve sredstv rannego lecheniia ostroĭ luchevoĭ bolezni v éksperimente.